Long only, growth, momentum, contrarian

Idera Phase 2 Data Provides For Exciting Q4 2013 And Q1 2014

Idera Pharmaceuticals (NASDAQ:IDRA) announced on June 5th that it had initiated enrollment in a Phase 2 trial of IMO-8400, one of its lead drug candidates, for patients with mild to severe plaque psoriasis. The announcement was a bit more significant than many investors were aware of apparently, as there was little share price or volume response with only 127,250 shares changing hands that day. Buried in the announcement was the phrase announcing "Data from the Phase 1 study will be presented at a scientific meeting in June 2013." The data was indeed presented in June and subsequently announced on July 1st via a corporate press release. The data were promising in the single...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details